PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDrax Regulatory News (DRX)

Share Price Information for Drax (DRX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 561.00
Bid: 559.00
Ask: 560.00
Change: -4.00 (-0.71%)
Spread: 1.00 (0.179%)
Open: 566.00
High: 572.00
Low: 557.50
Prev. Close: 565.00
DRX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Pricing of offering of Senior Secured Notes

18 Apr 2024 17:01

RNS Number : 2275L
Drax Group PLC
18 April 2024
 

18 April 2024

 

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN OR INTO AUSTRALIA, CANADA OR JAPAN OR IN ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES OF SECURITIES WOULD BE PROHIBITED BY APPLICABLE LAW. PLEASE SEE THE IMPORTANT NOTICES AT THE END OF THIS RELEASE.

Drax Group plc(LSE: DRX)

Pricing of offering of five-year Senior Secured Notes

Drax Group plc ("Drax") today announced that its indirect wholly owned subsidiary, Drax Finco plc (the "Issuer"), priced its offering (the "Offering") of euro denominated five-year senior secured notes (the "Notes") in an aggregate principal amount of €350 million.

The Notes will bear interest at an interest rate of 5.875% per cent. per annum and will be issued at 100 per cent. of their nominal value. The Notes will extend the Group's average debt maturity profile.

Drax intend to use the gross proceeds of the Offering (i) for general corporate purposes, which may include the repayment of indebtedness, and (ii) to pay estimated fees and expenses of the Offering, including Initial Purchasers' fees and commissions, professional fees and other associated transaction costs.

Enquiries:

Drax Investor Relations: Mark Strafford

mark.strafford@drax.com

+44 (0) 7730 763 949

 

Media:

Drax External Communications: Andy Low

andrew.low@drax.com

+44 (0) 7841 068 415

 

Website: www.drax.com

Cautionary Statement

This release is being issued pursuant to Rule 135c under the U.S. Securities Act of 1933, as amended (the "Securities Act") and is for information purposes only and does not constitute a prospectus or any offer to sell or the solicitation of an offer to buy any security in the United States of America or in any other jurisdiction. The Notes have not been and will not be registered under the Securities Act, and may not be offered or sold in the United States of America absent registration or an exemption from registration under the Securities Act. The Notes and related guarantees were offered in a private offering exempt from the registration requirements of the Securities Act and were accordingly offered only to non-U.S. persons, in offshore transactions, as defined in and in reliance on Regulation S under the Securities Act. No indebtedness incurred in connection with any other financing transactions will be registered under the Securities Act.

This communication is directed only at persons who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 as amended (the "Order"), (ii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations, etc.") of the Order, (iii) are persons who are outside the United Kingdom, or (iv) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with the issue or sale of any notes may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "relevant persons").

Any investment activity to which this communication relates will only be available to, and will only be engaged in with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.

This announcement is not a public offering in the Grand Duchy of Luxembourg or an offer of securities to the public under Regulation (EU) 2017/1129, and any amendments thereto.

The Notes are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail investor in the European Economic Area (the "EEA") or in the United Kingdom (the "UK"). For these purposes, a retail investor means a person who is one (or more) of: (i) a retail client as defined in point (11) of Article 4(1) of Article 4(1) of MiFID II; (ii) a customer within the meaning of the Insurance Distribution Directive), where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MiFID II; or (iii) not a qualified investor as defined in Regulation (EU) 2017/1129 (as amended, the "Prospectus Regulation"). Consequently no key information document required by Regulation (EU) No 1286/2014 (as amended, the "PRIIPs Regulation") for offering or selling the Notes or otherwise making them available to retail investors in the EEA or in the UK will be prepared. Offering or selling the Notes or otherwise making them available to any retail investor in the EEA or in the UK may be unlawful under the PRIIPs Regulation. Any offer of Notes in any Member State of the EEA or in the UK will be made pursuant to an exemption under the Prospectus Regulation from the requirement to publish a prospectus for offers of Notes.

The Manufacturer target market (MiFID II product governance) is eligible counterparties and professional clients only (all distribution channels).

In connection with any issuance of the Notes, a stabilising manager (or person(s) acting on behalf of such stabilising manager) may over-allot Notes or effect transactions with a view to supporting the market price of the Notes at a level higher than that which might otherwise prevail. However, stabilisation may not necessarily occur. Any stabilisation action may begin on or after the date on which adequate public disclosure of the terms of the offer of the Notes is made and, if begun, may be ended at any time, but it must end no later than 30 days after the date on which the issuer received the proceeds of the issue, or no later than 60 days after the date of the allotment of the Notes, whichever is earlier. Any stabilisation action or over-allotment must be conducted by the stabilising manager (or person(s) acting on behalf of the stabilising manager) in accordance with all applicable laws and rules.

Forward Looking Statements

This release includes forward-looking statements within the meaning of the securities laws of certain applicable jurisdictions. These forward-looking statements can be identified by the use of forward-looking terminology, including, but not limited to, terms such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "forecast", "guidance", "intend", "may", "outlook", "plan", "predict", "project", "should", "will" or "would" or, in each case, their negative, or other variations or comparable terminology. These forward-looking statements include, but are not limited to, all statements other than statements of historical facts and include statements regarding Drax's intentions, beliefs or current expectations concerning, among other things, Drax's future financial conditions and performance, results of operations and liquidity, strategy, plans, objectives, prospects, growth, goals and targets, future developments in the markets in which Drax participate or are seeking to participate, and anticipated regulatory changes in the industry in which Drax operate. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors because they relate to events and depend on circumstances that may or may not occur in the future. Readers are cautioned that forward-looking statements are not guarantees of future performance and are based on numerous assumptions. Given these risks and uncertainties, readers should not rely on forward looking statements as a prediction of actual results.

END

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IODGPUBACUPCGAR
Date   Source Headline
21st Feb 20249:32 amRNSHolding(s) in Company
15th Feb 202410:51 amRNSHolding(s) in Company
13th Feb 202412:47 pmRNSHolding(s) in Company
7th Feb 202410:32 amRNSHolding(s) in Company
1st Feb 202411:56 amRNSTotal Voting Rights
31st Jan 20243:16 pmRNSHolding(s) in Company
30th Jan 20242:15 pmRNSHolding(s) in Company
30th Jan 20248:45 amRNSAdditional Listing
29th Jan 20243:02 pmRNSHolding(s) in Company
25th Jan 20249:37 amRNSHolding(s) in Company
23rd Jan 20243:43 pmRNSHolding(s) in Company
18th Jan 202411:54 amRNSBridging Mechanism Consultation
16th Jan 20249:25 amRNSHolding(s) in Company
12th Jan 20243:29 pmRNSHolding(s) in Company
10th Jan 20241:22 pmRNSHolding(s) in Company
2nd Jan 202412:50 pmRNSTotal Voting Rights
27th Dec 20234:59 pmRNSHolding(s) in Company
20th Dec 20231:13 pmRNSDevelopment of UK CCS and BECCS business model
18th Dec 20238:45 amRNSAdditional Listing
5th Dec 20234:10 pmRNSTotal Voting Rights
5th Dec 20237:00 amRNSTrading Update
30th Nov 202311:03 amRNSHolding(s) in Company
29th Nov 20233:28 pmRNSHolding(s) in Company
27th Nov 20234:32 pmRNSHolding(s) in Company
13th Nov 202312:10 pmRNSHolding(s) in Company
8th Nov 20234:17 pmRNSHolding(s) in Company
2nd Nov 202311:42 amRNSHolding(s) in Company
1st Nov 20239:42 amRNSTotal Voting Rights
30th Oct 20238:30 amRNSDirector/PDMR Shareholding
27th Oct 20232:21 pmRNSHolding(s) in Company
24th Oct 20234:53 pmRNSHolding(s) in Company
23rd Oct 202311:32 amRNSHolding(s) in Company
20th Oct 202311:51 amRNSHolding(s) in Company
19th Oct 20234:46 pmRNSHolding(s) in Company
13th Oct 20234:00 pmRNSHolding(s) in Company
5th Oct 20239:58 amRNSHolding(s) in Company
4th Oct 202310:11 amRNSBlock listing Interim Review
4th Oct 202310:07 amRNSBlock listing Interim Review
4th Oct 20239:59 amRNSBlock listing Interim Review
4th Oct 20239:57 amRNSBlock listing Interim Review
4th Oct 20239:44 amRNSHolding(s) in Company
3rd Oct 202310:05 amRNSTotal Voting Rights
28th Sep 20232:35 pmRNSDirector/PDMR Shareholding
28th Sep 20238:30 amRNSAdditional Listing
26th Sep 20235:29 pmRNSHolding(s) in Company
26th Sep 20231:30 pmRNSDirector/PDMR Shareholding
26th Sep 202312:44 pmRNSDirector/PDMR Shareholding
26th Sep 20237:25 amRNSTrack-1 expansion process update
22nd Sep 20233:41 pmRNSHolding(s) in Company
20th Sep 20234:14 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.